









Markets
/
Stocks
/
nasdaq-biib
/

Biogen Inc

BIIB

142.500USD

-1.310-0.91%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

20.89BMarket Cap

13.65P/E TTM



Biogen Inc

142.500

-1.310-0.91%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

15 / 175

Overall Ranking

92 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 35 analysts

Buy

Current Rating

169.080

Target Price

+17.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Fairly Valued

The company’s latest PE is 13.61, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 135.74M shares, decreasing 8.55% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 17.21M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.39, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.65B, representing a year-over-year increase of 7.33%, while its net profit experienced a year-over-year increase of 8.77%.

Score

Industry at a Glance

Previous score

8.39

Change



Financials

7.03

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 5.60, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 13.73, which is 72.71% below the recent high of 23.71 and 2.41% above the recent low of 13.40.

Score

Industry at a Glance

Previous score

5.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 15/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.14, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Biogen Inc is 152.00, with a high of 260.00 and a low of 118.00.

Score

Industry at a Glance

Previous score

7.14

Change

Support & Resistance

No Data

Analyst Rating

Based on 35 analysts

Buy

Current Rating

169.080

Target Price

+17.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.63, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 152.22 and the support level at 133.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.63

Change

-1.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.244

Neutral

RSI(14)

55.140

Neutral

STOCH(KDJ)(9,3,3)

40.777

Sell

ATR(14)

4.755

Low Volatility

CCI(14)

-2.639

Neutral

Williams %R

46.448

Neutral

TRIX(12,20)

0.331

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

143.636

Sell

MA10

143.944

Sell

MA20

140.746

Buy

MA50

135.053

Buy

MA100

131.266

Buy

MA200

136.038

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 92.58%, representing a quarter-over-quarter decrease of 0.85%. The largest institutional shareholder is The Vanguard, holding a total of 17.21M shares, representing 11.74% of shares outstanding, with 2.58% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

16.96M

+1.67%

PRIMECAP Management Company

Star Investors

15.94M

-0.64%

BlackRock Institutional Trust Company, N.A.

8.70M

+1.24%

State Street Global Advisors (US)

7.40M

-0.02%

Wellington Management Company, LLP

4.67M

-5.24%

Geode Capital Management, L.L.C.

3.85M

+4.10%

Invesco Capital Management (QQQ Trust)

3.03M

-0.28%

Norges Bank Investment Management (NBIM)

2.33M

+11.86%

Invesco Capital Management LLC

Star Investors

2.01M

+6.62%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.18, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.12. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.